Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources Group
Cardiac Resynchronization Therapy Devices Will Experience the Fastest Growth, According to Findings from Decision Resources Group
BURLINGTON, Mass., May 6, 2014 /PRNewswire/ -- Decision Resources Group finds that cardiac rhythm management (CRM) device implantations in China will expand strongly through 2022 as the population ages and the incidences of obesity and hypertension rise with more affluent, sedentary lifestyles. Improving health care infrastructure and reimbursement will also bring these procedures within reach of a larger proportion of the Chinese population. As a result, the market will grow to over $1.1 billion by 2022.
Other key findings from the Medtech 360 report entitled Chinese Markets for Cardiac Rhythm Management Devices 2014:
Comments from Decision Resources Group Analyst Darren Lin:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.